Research Updates

A comprehensive set of summaries from the MDS Foundation highlighting notable low- and high-risk MDS studies presented at ASH 2025.

Multiple organisations will present new clinical, translational, and patient-focused research at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include advances in targeted and combination therapies for MDS and AML, emerging immunotherapies, expanded data on all-oral treatment regimens, and real-world outcomes studies, alongside new evidence on the impact of patient education and shared decision-making.

A large BMT CTN trial (1702) found that patients—including those with myelodysplastic syndromes—did just as well at ~2 years when proceeding to transplant with an alternate (mismatched) donor rather than delaying for a fully matched one. The takeaway: timing matters more than perfection—speak with your care team about the best window for transplant.

Faron announced plans to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA.

Ascentage Pharma announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

Sent Biosciences announced it has confirmed the recommended Phase 2 dose (RP2D) in its Phase 1 study of SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML).

Faron Pharmaceuticals announced that new clinical and translational data from the Phase I/II BEXMAB study evaluating bexmarilimab in combination with azacitidine in higher-risk myelodysplastic syndromes (HR-MDS) will be presented as a part of a Mini Oral Abstract Session at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place from October 17-21, 2025, in Berlin, Germany.

Servier announced that long-term efficacy and safety results, published in Blood Advances, continue to demonstrate the sustained survival benefit of adding TIBSOVO to azacitidine in IDH1-mutated AML.